close

IMI launches two new calls to appeal to a wide range of stakeholders

The world’s largest public-private partnership in life sciences, the Innovative Medicines Initiative (IMI), has launched two new Calls for proposals, offering stakeholders from a variety of sectors the opportunity to take part in scientifically excellent, patient-centric research. The ultimate aim is to develop the right prevention and treatment for the right patient at the right time.

Among other projects, Call 7 will focus on: dry age-related macular degeneration (development of novel clinical endpoints for clinical trials with a regulatory and patient access intention); identification of druggable targets modulating misfolded proteins in Alzheimer’s and Parkinson’s diseases; and a comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule development for children with cancer topics under the Big Data for Better Outcomes programme.

There is also increased emphasis on the Big Data for Better Outcomes programme, including: Coordination and Support Actions (CSA) for the programme; and a drive to increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients.

Call 8 focuses on proposals in the area of Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks. The main objectives of projects funded under the Ebola+ programme will be to realise outputs that increase our preparedness to react to future outbreaks of Ebola and other filoviral haemorrhagic fevers.

Further information about Calls 7 and 8 can be found here